Interventions for Tuberculosis Control and Elimination 2002

1067. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study
of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis.
1992; 102: 1815-8.
Chest
1068. Casal M, Ruiz P, Herreras A. Study of the in vitro susceptibility of M. tuberculosis
to ofloxacin in Spain. Int J Tuberc Lung Dis 2000; 4: 588-91.
1069. Global Alliance for TB Drug Development. Scientific blueprint for tuberculosis
drug development. Tuberculosis 2001; 81(suppl 1): 1-52.
1070. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals
versus children. Clin Infect Dis 1997; 25: 1196-204.
1071. Post FA, Wood R. Tuberculous pleural effusions in HIV-positive patients.
(Correspondence). Int J Tuberc Lung Dis 1998; 2: 941.
1072. Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of
drugs. An update. Clin Pharmacokinetics 1990; 18: 210-9.
1073. Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA.
Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium
tuberculosis selected in the laboratory and isolated from patients.
Agents Chemother 1995; 39: 1700-3.
Antimicrob
1074. Cambau E, Jarlier V.
1996; 147: 52-9.
Resistance to quinolones in mycobacteria. Res Microbiol
1075. Berning SE.
61: 9-18.
The role of fluoroquinolones in tuberculosis today. Drugs 2001;
1076. Brogden RN, Fitton A. Rifabutin. A review of its antimicrobial activity, pharmacokinetic
properties and therapeutic efficacy. Drugs 1994; 47: 983-1009.
1077. Marsili L, Pasqualucci CR, Vigevani A, Gioia B, Schioppacassi G, Oronzo G.
New rifamycins modified at positions 3 and 4. Synthesis, structure and biological
evaluation. J Antibiotics 1981; 24: 1033-8.
1078. O’Brien RJ, Lyle MA, Snider DE. Rifabutin (ansamycin LM 427): a new
rifamycin-S derivative for the treatment of mycobacterial diseases.
Dis 1987; 9: 519-30.
Rev Infect
1079. Kunin CM.
S3-S14.
Antimicrobial activity of rifabutin. Clin Infect Dis 1996; 22 (Suppl):
1080. Heifets LB, Iseman MD. Determination of in vitro susceptibility of mycobacteria
to ansamycin. Am Rev Respir Dis 1985; 132: 710-1.
1081. Woodley CL, Kilburn JO. In vitro susceptibility of Mycobacterium avium complex
and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.
Am Rev Respir Dis 1982; 126: 586-7.
1082. Gangadharam PRJ, Perumal VK, Jairam BT, Rao PN, Nguyen AK, Farhi DC,
Iseman MD. Activity of rifabutin alone or in combination with clofazimine or
ethambutol or both against acute and chronic experimental Mycobacterium intracellulare
infections. Am Rev Respir Dis 1987; 136: 329-33.
241